Zhangzhou Pientzehuang Pharmaceutical (600436) H2 2024 earnings summary

Executive summary

• Revenue reached RMB 10.79 billion, up 7.25% year-over-year; net profit attributable to shareholders was RMB 2.98 billion, up 6.42% year-over-year.

• Gross margin was 42.84%, down 3.98 percentage points year-over-year; cash dividend payout ratio for the year was 60.19%.

• R&D investment increased to RMB 269.6 million, accounting for 2.5% of revenue; sales expenses dropped 33.88% due to reduced promotional and advertising costs.

• The company maintained a strong balance sheet with total assets of RMB 17.54 billion and net assets of RMB 14.27 billion at year-end.

• No material risks affecting operations were identified during the reporting period.

Financial highlights

• Operating income: RMB 10.79 billion, up 7.25% year-over-year; net profit: RMB 2.98 billion, up 6.42%.

• Basic EPS: RMB 4.93, up 6.25% year-over-year; weighted average ROE: 21.36%.

• Operating cash flow: RMB 1.31 billion, down 40.47% year-over-year, mainly due to increased raw material purchases.

• Gross margin: 42.84%, down 3.98 percentage points year-over-year; R&D expenses: RMB 269.6 million, up 16% year-over-year.

• Cash dividend: RMB 1.79 billion, representing 60.19% of net profit attributable to shareholders.

Outlook and guidance

• Plans to further expand in pharmaceuticals, innovative drugs, and health/beauty sectors, aiming to strengthen the core brand and scale up operations.

• R&D focus on new drug projects, with 2 new projects and 3–5 clinical studies planned for 2025.

• Will continue to fill gaps in traditional medicine channels, expand retail presence, and explore new media and retail scenarios.

• Will monitor policy, market, and raw material risks, and maintain high R&D investment to sustain high-tech enterprise status.